Loading
A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma is a phase 2 interventional study registered as NCT06550895 by Janssen Research & Development, LLC, with 11 participants enrolled, started 2024-09-16 and due to reach its primary completion in 2027-08-26. Interventions recorded: Cilta-cel, Talquetamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Ciltacabtagene autoleucel, Johnson & Johnson, T-cell engagers (bispecific).
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
Shares Talquetamab, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.